PLEASE SIGN IN
(NAME AND EMAIL)

AANS/CNS
Cerebrovascular Section

Executive Council Meeting, CV Sect 2012

Monday, January 30, 2012
Belle Chase Room
Hilton New Orleans Riverside Hotel
New Orleans, LA 5:00-6:00pm
Approval of Minutes
Dr. Sean D. Lavine
Meeting Agenda

Call to Order (Dr. Connolly)

Approval of Minutes from CNS 2011 (Dr. Lavine)

Moment of Silence (Remembrance Christopher C. Getch, MD, 1961-2012)

Treasurer’s Report (Dr. Hoh)

Annual Meeting Updates
- 2012 CV Annual Meeting (Dr Ringer)
- 2012 ISC Meeting (Drs Albuquerque, Carter, Patel)
- 2012 AANS Meeting (Drs Bulsara and Bambakidis)

Standing Committee/Project Updates
- Coding & Reimbursement (Dr Vates)
- Joint Guidelines Committee/CV Section Guidelines Committee (Dr. Hanjani)
- National Quality Forum (Dr Cockroft)
- Endovascular Task Force (Dr Thompson)
- Neurovascular Coalition (Drs. Wilson and Cockroft)
- SNIS update (Dr Felipe Albuquerque)
- Brain Attack Coalition (Dr. Huang)
- Membership Update (Dr. Zipfel)
- Fundraising Committee (Drs. Hoh and Rasmussen)
- Research Fellowship (Drs. Dempsey and Rasmussen)
- Newsletter Committee (Drs. David and Bulsara)
- Website Committee (Drs Zipfel and Carter)
- Curriculum Development and Education Committee (Dr. Bendok)
- Bylaws/Rules & Regulations Committee (Dr. Prestigiaco)

Old Business Updates
- Junior Resident Endovascular Course (Drs Mocco, Bendok)
- Neuropoint Alliance (Dr Cockroft)
- 3C meeting (Drs Levy, Siddiqui)
- Joint Meeting – Cerebrovascular Society of India (Abdulrauf)
- Brain Aneurysm Foundation (Dr David)

New Business
- COSS Trial Statement by CV Sect (Dr. Hanjani)
- MedCAC Voting on Carotid Atherosclerosis (Dr Wilson)
- Senior Society Matrix/Milestones and Modules (Connolly)
- Massimo Collie award for cerebrovascular malformations
- SVIN Liaison (Dr Mocco)
In Memoriam... CNS Past-President, Christopher C. Getch, MD, 1961-2012

The CNS suffered a tragic and unexpected loss on Monday, January 9 with the news of Dr. Christopher C. Getch's untimely death.

Dr. Getch, the immediate past-president of the Congress of Neurological Surgeons, was an inspiring leader who worked tirelessly on behalf of the CNS, its members, and the profession of Neurosurgery. He will be remembered by all as a great father, husband, leader, surgeon, and friend.

In less than 15 years, Dr. Getch rose to the top of national neurosurgical leadership, including progressively increased responsibility with the Congress of Neurological Surgeons, culminating with his role as president from 2010 to 2011. Dr. Getch was also president of the Illinois State Neurosurgical Society and had been an active member in the Medical Faculty Senate Council for Northwestern University and several Northwestern Memorial Hospital committees. Dr. Getch spent his entire faculty career at Northwestern, joining the Feinberg School of Medicine in 1996 as an assistant professor in the Department of Neurosurgery. He was twice promoted, to associate professor in 2005, and professor in 2010. After growing up in Boston, Dr. Getch earned his medical degree at Tufts University School of Medicine. His residencies in neurological surgery were at Temple University Hospital and Thomas Jefferson University Hospital, both in Philadelphia. He also was a clinical fellow of neurological surgery at the University of Pittsburgh, where he completed fellowships in microsurgery and stereotactic radiosurgery.

Joining the Illinois State Neurosurgical Society in 1996 upon moving to Chicago, Dr. Getch was actively involved in the society’s efforts on liability reform and the practice of defensive medicine by neurosurgeons. Dr. Getch had been involved in resident education at Northwestern since joining the faculty, and more recently as a regional director of the Senior Society Boot Camp course.

His clinical research interests included the surgical and stereotactic radiosurgical treatment of cerebrovascular disease. Additionally, he had extensive experience with posterior fossa surgery, particularly in the treatment of trigeminal neuralgia. His academic work generated 75 publications and 30 published abstracts.

Dr. Getch is survived by his wife, Gale England, GME ’00, a surgeon who trained at Northwestern, and four sons, Christopher, Oliver, Charles, and William.

As an alternative to, or in lieu of flowers, the family suggested that a donation in the memory of Chris can be made to Midwest Labrador Retriever Rescue, where Dr. Getch and Gale adopted their beloved lab, Wilbur Gale.
Treasurer’s Report
Dr. Brian Hoh
# AANS/CNS Section on Cerebrovascular Surgery
## Statement of Financial Position
### As of December 31, 2011 and 2010

<table>
<thead>
<tr>
<th></th>
<th>Current Year 12/31/11</th>
<th>Prior Year 12/31/10</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Checking &amp; Short Term Investments</td>
<td>$183,876</td>
<td>$181,131</td>
</tr>
<tr>
<td>Accounts Receivable, net of Allowance for Uncollectible Accounts</td>
<td>108,100</td>
<td>89,886</td>
</tr>
<tr>
<td>Prepaid Expenses</td>
<td></td>
<td>30,000</td>
</tr>
<tr>
<td>Long-Term Investment Pool, at Market</td>
<td>564,159</td>
<td>572,348</td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td>$856,134</td>
<td>$873,365</td>
</tr>
<tr>
<td><strong>LIABILITIES AND NET ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Liabilities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deferred Dues</td>
<td>60,300</td>
<td>56,950</td>
</tr>
<tr>
<td><strong>Total Liabilities</strong></td>
<td><strong>$60,300</strong></td>
<td><strong>$56,950</strong></td>
</tr>
<tr>
<td><strong>Net Assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unrestricted</td>
<td>$554,937</td>
<td>$440,568</td>
</tr>
<tr>
<td>Unrestricted - Donaghy</td>
<td>$48,684</td>
<td>$43,490</td>
</tr>
<tr>
<td>Unrestricted - Galbraith</td>
<td>$26,762</td>
<td>$24,239</td>
</tr>
<tr>
<td>Unrestricted - Resident</td>
<td>$17,033</td>
<td>$23,043</td>
</tr>
<tr>
<td>Unrestricted - Leussenhop</td>
<td>$19,924</td>
<td>$19,273</td>
</tr>
<tr>
<td>Unrestricted - Drake</td>
<td>$10,415</td>
<td>$9,678</td>
</tr>
<tr>
<td>Unrestricted - Yasargil Lectureship</td>
<td>$52,727</td>
<td></td>
</tr>
<tr>
<td><strong>Total Revenue (Expense)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total Net Assets</strong></td>
<td><strong>$795,834</strong></td>
<td><strong>$816,415</strong></td>
</tr>
<tr>
<td><strong>TOTAL LIABILITIES AND NET ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>$856,134</strong></td>
<td><strong>$873,365</strong></td>
</tr>
</tbody>
</table>
## AANS/CNS Section on Cerebrovascular Surgery

**Statement of Activities**

For the Six Months Ending December 31, 2011

<table>
<thead>
<tr>
<th></th>
<th>FY ’08</th>
<th>FY ’09</th>
<th>FY ’10</th>
<th>FY ’11</th>
<th>YTD</th>
<th>FY ’12</th>
<th>Budget</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Final</td>
<td>Final</td>
<td>Final</td>
<td>Final</td>
<td>FY ’12</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>REVENUES</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Membership Dues</td>
<td>$30,900</td>
<td>$34,563</td>
<td>$46,750</td>
<td>$54,648</td>
<td>$24,116</td>
<td>$54,900</td>
<td></td>
</tr>
<tr>
<td>Mailing List Sales</td>
<td>295</td>
<td>0</td>
<td>0</td>
<td>295</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Contributions/Sponsorships</td>
<td>17,500</td>
<td>27,500</td>
<td>7,500</td>
<td>85,000</td>
<td>7,773</td>
<td>37,500</td>
<td></td>
</tr>
<tr>
<td>Advertising Revenue</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1,300</td>
<td>0</td>
<td>1,300</td>
<td></td>
</tr>
<tr>
<td>Miscellaneous Revenue</td>
<td>325</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Contributions for Operating Expenses</td>
<td>7,925</td>
<td>8,661</td>
<td>9,143</td>
<td>9,347</td>
<td>4,260</td>
<td>10,200</td>
<td></td>
</tr>
<tr>
<td>Annual Meeting Revenue</td>
<td>220,437</td>
<td>93,785</td>
<td>167,709</td>
<td>255,771</td>
<td>149,625</td>
<td>235,078</td>
<td></td>
</tr>
<tr>
<td><strong>TOTAL REVENUES &amp; SUPPORT</strong></td>
<td>$277,382</td>
<td>$164,509</td>
<td>$231,102</td>
<td>$406,361</td>
<td>$185,774</td>
<td>$338,978</td>
<td></td>
</tr>
<tr>
<td><strong>EXPENSES</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Audio Visual</td>
<td>$2,152</td>
<td>$1,874</td>
<td>$1,477</td>
<td>$1,192</td>
<td></td>
<td>$1,500</td>
<td></td>
</tr>
<tr>
<td>Bank Fee</td>
<td>423</td>
<td>535</td>
<td>518</td>
<td>930</td>
<td>277</td>
<td>780</td>
<td></td>
</tr>
<tr>
<td>Contributions &amp; Affiliations</td>
<td>110,000</td>
<td>10,000</td>
<td>60,000</td>
<td>10,000</td>
<td>0</td>
<td>10,000</td>
<td></td>
</tr>
<tr>
<td>Decorating</td>
<td>0</td>
<td>205</td>
<td>607</td>
<td>741</td>
<td>0</td>
<td>350</td>
<td></td>
</tr>
<tr>
<td>Food &amp; Beverage</td>
<td>3,812</td>
<td>5,498</td>
<td>8,160</td>
<td>9,959</td>
<td>2,222</td>
<td>10,000</td>
<td></td>
</tr>
<tr>
<td>Honoraria &amp; Awards</td>
<td>33,734</td>
<td>35,407</td>
<td>35,690</td>
<td>40,960</td>
<td>30,000</td>
<td>36,000</td>
<td></td>
</tr>
<tr>
<td>Office &amp; Other Supplies</td>
<td>271</td>
<td>448</td>
<td>343</td>
<td>200</td>
<td>58</td>
<td>450</td>
<td></td>
</tr>
<tr>
<td>Photocopy</td>
<td>3</td>
<td>1</td>
<td>95</td>
<td>1</td>
<td>0</td>
<td>25</td>
<td></td>
</tr>
<tr>
<td>Postage &amp; Distribution</td>
<td>462</td>
<td>595</td>
<td>468</td>
<td>901</td>
<td>1,184</td>
<td>825</td>
<td></td>
</tr>
<tr>
<td>Printing/Typesetting</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1,282</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Newsletter Postage</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>998</td>
<td>0</td>
<td>1,025</td>
<td></td>
</tr>
<tr>
<td>Newsletter Printing</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2,015</td>
<td>0</td>
<td>2,025</td>
<td></td>
</tr>
<tr>
<td>Newsletter Professional Fees</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>195</td>
<td>0</td>
<td>200</td>
<td></td>
</tr>
<tr>
<td>Website</td>
<td>0</td>
<td>0</td>
<td>540</td>
<td>699</td>
<td>600</td>
<td>1,190</td>
<td></td>
</tr>
<tr>
<td>Staff Travel</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>225</td>
<td></td>
</tr>
<tr>
<td>Telephone</td>
<td>109</td>
<td>120</td>
<td>566</td>
<td>268</td>
<td>152</td>
<td>325</td>
<td></td>
</tr>
<tr>
<td>Temporary Personnel</td>
<td>38,479</td>
<td>7,500</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Volunteer Travel</td>
<td>3,379</td>
<td>1,140</td>
<td>386</td>
<td>0</td>
<td>0</td>
<td>1,000</td>
<td></td>
</tr>
<tr>
<td>Staff Coordination</td>
<td>9,864</td>
<td>9,259</td>
<td>10,081</td>
<td>11,539</td>
<td>4,870</td>
<td>18,142</td>
<td></td>
</tr>
<tr>
<td>Annual Meeting Expense</td>
<td>121,583</td>
<td>134,752</td>
<td>198,562</td>
<td>239,529</td>
<td>50,982</td>
<td>266,556</td>
<td></td>
</tr>
<tr>
<td><strong>TOTAL EXPENSES</strong></td>
<td>$324,271</td>
<td>$207,334</td>
<td>$317,693</td>
<td>$321,409</td>
<td>$90,345</td>
<td>$340,618</td>
<td></td>
</tr>
<tr>
<td>Investment Earnings</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(12,438)</td>
<td></td>
<td>(82,961)</td>
<td>55,192</td>
<td>85,240</td>
<td>(30,078)</td>
<td>27,168</td>
<td></td>
</tr>
<tr>
<td><strong>NET REVENUE</strong></td>
<td>($59,327)</td>
<td>($125,786)</td>
<td>($31,399)</td>
<td>$170,192</td>
<td>$65,351</td>
<td>$25,528</td>
<td></td>
</tr>
</tbody>
</table>
## AANS/CNS Section on Cerebrovascular Surgery
### Annual Meeting
#### For the Six Months Ending December 31, 2011

<table>
<thead>
<tr>
<th></th>
<th>FY '08 Final</th>
<th>FY '09 Final</th>
<th>FY '10 Final</th>
<th>FY '11 Final</th>
<th>YTD FY '12</th>
<th>FY '12 Budget</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenues</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Registration Fees</td>
<td>46,751</td>
<td>37,250</td>
<td>48,500</td>
<td>66,625</td>
<td>28,750</td>
<td>88,500</td>
</tr>
<tr>
<td>Exhibitor Fees</td>
<td>70,850</td>
<td>43,200</td>
<td>53,200</td>
<td>59,275</td>
<td>40,200</td>
<td>49,200</td>
</tr>
<tr>
<td>Exhibitor Sponsorship Revenue</td>
<td>100,000</td>
<td>6,000</td>
<td>15,000</td>
<td>29,000</td>
<td>15,000</td>
<td>20,000</td>
</tr>
<tr>
<td>Resident Hands-on Course Revenue</td>
<td>0</td>
<td>0</td>
<td>44,100</td>
<td>84,000</td>
<td>66,000</td>
<td>70,000</td>
</tr>
<tr>
<td>Special Event Revenues</td>
<td>1,350</td>
<td>1,425</td>
<td>1,725</td>
<td>6,675</td>
<td>675</td>
<td>3,000</td>
</tr>
<tr>
<td>Housing/Reg/Tape Revenue</td>
<td>1,486</td>
<td>5,910</td>
<td>5,184</td>
<td>10,196</td>
<td>0</td>
<td>4,378</td>
</tr>
<tr>
<td><strong>Total Revenues</strong></td>
<td>220,437</td>
<td>93,785</td>
<td>167,709</td>
<td>255,771</td>
<td>149,625</td>
<td>235,078</td>
</tr>
</tbody>
</table>

| **Expenses**         |              |              |              |              |            |              |
| Scientific Program   | 22,209       | 40,553       | 39,685       | 46,091       | 11,489     | 51,564       |
| Poster Session       | 0            | 3,558        | 4,941        | 5,016        | 0          | 5,602        |
| Abstract Management  | 79           | 0            | 0            | 0            | 0          | 0            |
| Program Book         | 2,282        | 13,083       | 14,785       | 11,331       | 1,300      | 11,500       |
| Special Course       | 0            | 0            | 3,026        | 3,920        | 0          | 3,108        |
| Opening Reception    | 11,361       | 18,804       | 21,197       | 30,876       | 0          | 19,496       |
| Committee Dinners/Events | 2,987 | 5,720       | 5,422        | 4,787        | 0          | 5,200        |
| Exhibit Program      | 2,724        | 3,226        | 5,729        | 9,122        | 1,000      | 6,060        |
| Exhibit Marketing    | 0            | 2,848        | 2,289        | 1,025        | 1,950      | 1,500        |
| Advanced Registration| 11,570       | 11,544       | 12,425       | 13,795       | 10,171     | 14,200       |
| On-Site Registration | 399          | 4,543        | 1,470        | 2,214        | 0          | 5,175        |
| Preliminary Program  | 813          | 2,497        | 2,932        | 950          | 0          | 950          |
| Annual Meeting Promotion | 2,000 | 3,636       | 3,316        | 2,328        | 945        | 1,300        |
| On-Site Coordination | 1,201        | 4,382        | 5,908        | 5,073        | 268        | 7,900        |
| Scientific Program Planning Cmte | 0 | 0           | 0            | 0            | 0          | 0            |
| Annual Meeting Cmte  | 672          | 24           | 0            | 0            | 0          | 0            |
| Staff Coordination   | 63,285       | 20,334       | 32,302       | 34,540       | 23,858     | 41,550       |
| Resident Hands-on Course Expenses | 0 | 43,134     | 68,463       | 0            | 81,452     |              |
| **Total Expenses**   | 121,583      | 134,752      | 198,562      | 239,529      | 50,982     | 256,556      |

| **Net Excess (Loss)**| 98,854       | (40,967)     | (30,854)     | 16,242       | 98,643     | (21,478)     |
AANS/CNS SECTION ON CEREBROVASCULAR SURGERY

NOTES TO FINANCIAL STATEMENTS

December 31, 2011

General and Administrative

Expense

Postage – Budget $825, Actual $1,184
1,004 certificates were mailed to CV Resident members in July 2011 at a cost of $.88 each per Dr. Zipfel.

Sponsorship Update - 12/31/11

CV Section

<table>
<thead>
<tr>
<th>Budgeted Sponsorships:</th>
<th>Budgeted Amount</th>
<th>Date Received</th>
<th>Amount Received</th>
</tr>
</thead>
<tbody>
<tr>
<td>Synthes</td>
<td>$ 7,500.00</td>
<td>10/6/2011</td>
<td>$ 7,500.00</td>
</tr>
<tr>
<td>Resident Research Award -1</td>
<td>$ 15,000.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resident Research Award -2</td>
<td>$ 15,000.00</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Total Amount Received for FY12

$ 7,500.00

Also received:

Return of Unused Grant Funds
11/2/2011 $ 273.46
(from Yale University - Resident Research Award)
CV Section 2012 New Orleans

- MONDAY, JANUARY 30, 2012
- 12:00 – 7:00 PM Registration
- 1:00 – 5:00 PM
- 2 Concurrent Practical Courses
- 6:00 - 7:30 PM
- Opening Reception in the Exhibit Hall
CV Section 2012 New Orleans

- **TUESDAY, JANUARY 31, 2012**
- 7:00 AM – 4:00 PM
  - Registration
- 7:00 – 8:00 AM
  - Continental Breakfast in Exhibit Hall
- 8:00 - 8:10 AM
  - Welcome
    - E. Sander Connolly, Jr. MD
    - AANS/CNS Cerebrovascular Section Chair
    - Andrew J. Ringer, MD, FAANS
    - Annual Meeting Chair
CV Section 2012 New Orleans

- 8:10 - 10:00 AM
- Scientific Symposium I – Ischemic Stroke and the Neurosurgeon (8:10-9:30)
  - Moderators: Rich Fessler and Jay Howington
  - Speakers:
    - Endovascular Techniques for Acute Revascularization (Ketan Bulsara)
    - Bypass Surgery: The Red-Headed Step Child (incl. COSS review) (Dave Langer)
    - Surgical and Endovascular Stroke Prevention (SAMMPRIS/CREST rev.) (Mark Chimowitz)
    - Hemicraniectomy for Stroke (Stephan Mayer)
- Oral Abstracts (4-5 abstracts, 5 minutes each w/ 1 minute for questions) (9:30-10)
10:00 - 10:30 AM

Coffee Break in the Exhibit Hall

10:00 - 4:30 PM

Exhibit Hall

10:30 - 12:00 PM

Scientific Symposium II – Aneurysms (10:30-11:30)

Moderators: Giussepe Lanzino and Shah-Naz Khan

Speakers:

- Giant aneurysm management: surgical, endovascular and combined (Carlos David)
- New endovascular techniques for aneurysms (liquid embolics, flow diverters) (J Mocco)
- A modern dilemma: The unruptured aneurysm (Andy Ringer)

Oral Abstracts (4-5 abstracts, 5 minutes each w/ 1 minute for questions) (11:30-12)
2:00 – 3:00 PM

- **Scientific Symposium III – Luessenhop**

- 2:00 – 2:15 PM
  - **Chair’s Address**
  - E. Sander Connolly, Jr. MD
  - AANS/CNS Cerebrovascular Section Chair

- 2:15-2:20 PM
  - **CV Section Resident Research Award**
  - Presentation of award - Cameron McDougal

- 2:20-2:25
  - **Introduction of Luessenhop Lecturer**
  - Kim Nelson

- 2:25 – 2:55 PM
  - **Luessenhop Lecture**

- 2:55 – 3:00 PM
  - **Question & Answer**
CV Section

- **Scientific Symposium IV – AVMs**
  - Moderators: Bernard Bendok and Alan Boulos
  - Speakers:
  - 3:00 - 4:00 PM
    - Embolization for Radiosurgery: A useful tool (point) (Babu Welch)
    - Embolization for Radiosurgery: A waste of time (counterpoint) (Gavin Britz)
    - A modern dilemma: The unbled AVM (ARUBA update) (Kevin Cockroft)
  - 4:00 - 4:30 PM
    - **Coffee Break in the Exhibit Hall**
CV Section

- 4:30 - 6:00 PM
- **Scientific Symposium V – ICH: Trials and Tribulations (4:30-5:30)**
- Moderators: Rafael Rodriguez and Adam Arthur
- Speakers:
  - Surgery for ICH (David Mendelow)
  - Minimally Invasive Surgery for ICH and IVH (Isaam Awad)
  - Coagulopathy, Anticoagulants and ICH (Joseph Beshay)
- Oral Abstracts (4 abstracts, 5 minutes each w/ 1 minute for questions)
  5:30-6pm
2012 ISC Conference
New Orleans, LA

Dr. Bob Carter
Dr Felipe Albuquerque
Dr Aman Patel
ISC Meeting
Ischemic Stroke:
Endovascular Treatment

Felipe C. Albuquerque, MD
Debate Session

- The Ethics of Device Use for Acute Stroke Intervention
Invited Symposium

- Imaging Biomarkers in Endovascular Stroke Therapy: Translation from Clinical Research to Practice
Academic Sessions

- 2 Oral Abstract Sessions
  - 4 moderators and 4 alternates from CV Section
  - 7 abstracts per session

- 2 Oral Poster Sessions
  - 2 moderators and 2 alternates from CV Section
  - 6 abstracts per session

- 2 General Poster Sessions
  - 37 abstracts total
CV Section Involvement: ISC 2012

- Connolly
- Cockroft
- Riina
- Hoh
- Siddiqui
- Zipfel
- Albuquerque
- Levy, E.
- Pandey
- Gunel
- Khalessi
- Barnwell
- McDougall
- Niemann

- Harbaugh
- Patel
- Woo
- Prestigiacomo
- Steinberg
- Rosenwasser
- Jabbour
- Dumont
- Stiefel
- Rasmussen
- Carter
- Lavine
- Dashti
- Arthur
- Lanzino
ISC 2013

- Preparations underway

- Suggested Session Submission
  Opens: 1/30/2012
  Closes: 3/5/2012

- Abstract Submission
  Opens: 5/23/2012
  Closes: 8/14/2012

- Late Breaking Science Submission
  Opens: 10/10/2012
  Closes: 11/7/2012
ISC 2012 – Vascular malformations
Aman Patel

- 2 symposiums
- Oral abstract session will be combined with aneurysm section
  - 3 Vascular malformation, 4 Aneurysm abstracts
- 6 moderated poster abstracts
- 4 posters
Symposiums

- Hemodynamic and Research Principles of AVMS – Friday Feb 3, 8am – 9:30 am
  - Aberrant Angiogenic Signaling And Animal Modeling Studies: William Young
  - Human Genetic Studies: Murat Gunel
  - Randomized Trials: Christian Staph
  - Animal Models of AVMs and What Have We Learned regarding Hemodynamics: Henry Woo
  - AVM Anatomy Relating to Hemodynamic Principles: Charles Prestigiacomo
Symposiums

- Seizures and Vascular Malformations: How to Treat?
  - Pathophysiology, Epidemiology and Diagnosis of Seizures in Patients with Vascular Malformations: Paul Vespa
  - Medical Management of Seizures in the Setting of Vascular Malformations: Madeline Fields
  - Surgical Planning in Seizures and Vascular Malformations: Domingos Coiteiro
  - Radiosurgery for the Treatment of Seizures in Vascular Malformations: Howard Riina
2012 AANS Conference
Miami, Fl

Dr. Ketan R. Bulsara
Dr. Nicholas Bambakidis
CEREBROVASCULAR SECTION (April 17th, 2012)

Section Day Layout

Speaker Slate (2:00 to 3:30)

Moderators: Ketan R. Bulsara and Nicholas Bambakidis

2:00 to 2:10  Sander Connolly  Introduction of Donaghy Lecturer
2:10 to 2:35  Robert Solomon  Donaghy Lecture
2:35 to 2:50  Jacques Morcos  Current Indications for EC-IC bypass: Fall out from COSS
2:50 to 3:05  Doug Kondziolka;  Pre-radiosurgery embolization for AVMs- helpful or harmful

3:05 to 3:20  Brian Hoh  SAMMPRIS and its implications

Abstract Section (4:00 to 5:30)

Moderators: Andy Ringer and Henry Woo

# of abstracts you would like presented in your section: 10

# of minutes for each abstract presentation: 8
Time slot you want abstracts presented in: 4:00-4:40 for abstracts 1-5
(10 minute buffer for speaker’s over time) 4:50 -5:30 PM for abstracts 6-10
Standing Committees/Project updates
Washington Committee Update

Katie Orrico
Rachel Groman
Coding and Reimbursement Subcommittee

Dr. Edward Vates
Dr. John Wilson
Joint Guidelines Committee & CV Section Guidelines Committee

Dr. Sepideh Amin-Hanjani
AHA/ASA projects: Joint Guidelines Committee

Flag ship guidelines: $1^\text{o}$ prevention, $2^\text{o}$ prevention, ICH, SAH, Acute Stroke, Rehab

Recently endorsed by AANS/CNS through JGC
- SAH guidelines: (Writing Committee Chair: Connolly; Official AANS/CNS representative designated: Hoh).

Recently reviewed by JGC subcommittee
- Acute Stroke guidelines: reviewed (CV designated peer reviewer: J Mocco; JGC review: Cockroft, Hoh, Khalessi, Mack + 4 non CV JGC members)

In process of re-commissioning:
- $2^\text{o}$ prevention: writing group development
AHA/ASA project: CV Section Guidelines Committee

Other projects reviewed

- **Definition of Stroke:** reviewed by CV GC for endorsement by AANS/CNS
  (Babu Welch, Ketan Bulsara, Henry Woo, Clemens Schirmer, Justin Fraser)

Other upcoming projects:

- **Unruptured Aneurysms Update:** Co-Chairs: Greg Thompson, Bob Brown –
  writing group being developed
- **Risk of Cervical Dissection after Chiropractic Manipulation:** AANS/CNS
  writing group rep: Felipe Albuquerque
- **Evaluation and Management of Malignant Infarctions:** AANS/CNS writing
  group rep: Bob Carter
- **Palliative and End of Life Care:**
  AANS/CNS writing group rep: Greg Zipfel

Other potential projects:

- Women’s Guidelines for Stroke
- Update on Brain AVMs
CV Section Guidelines Committee

- Roster updated August 2011
- Review of documents outside purview of JGC (consensus statements, scientific statements, advisory statements etc)
- Volunteers: please contact hanjani@uic.edu
  - EBM background
  - AHA/ASA membership, FAHA
  - COI
Endovascular Task Force

Dr. Greg Thompson
Neurovascular Coalition

Dr. John Wilson
SNIS Update

Dr Felipe Albuquerque
Update on the SNIS 2012

Felipe C. Albuquerque, MD
Member At Large, SNIS
Executive Committee

Joshua Hirsch
Michael Alexander
Phillip Meyers
Cameron McDougall
Colin Derdeyn
Don Heck
Felipe Albuquerque

David Fiorella
Don Frei
Charles Prestigiacomo
Jeffrey Sunshine
Peter Rasmussen
Raul Nogueira
Rob Tarr – non voting
Cooperative Projects

- Brain Attack Coalition – Stroke care issues
- Neurovascular Coalition – Neurovascular issues
- ACGME Endovascular Surgical Neuroradiology Fellowship
- Meeting programming
- Standards

Ischemic stroke

Performance and training standards for endovascular ischemic stroke treatment


ABSTRACT
Stroke is the third leading cause of death in the USA, Canada, Europe, and Japan. According to the American Heart Association and the American Stroke Association, there are now 700,000 new strokes each year, resulting in 200,000 deaths, or 1 of every 16 deaths, per year in the USA alone. Endovascular therapy for patients with acute ischemic stroke is an area of intense inves-
Standards

- Currently writing/revising standards pertaining to the management of spinal AVMs, tumor embolization, and intracranial atherosclerotic disease
Meetings

SNIS Annual Meeting
Colorado Springs, CO
630 attendees

Fellows course
45 attendees

Stroke Practicum at ASNR
Boston, MA
250 attendees
Meetings

- Currently in discussions with CV Section over joint meeting around ISC Honolulu in 2013
Initial publication July 2009 as a quarterly journal

Indexed in Thomson-Reuters 2010

Initial impact factor 1.07

Pub Med / Medline indexing September 2011

With increased U.S. and International submissions will transition to bi-monthly publication in January 2012
Societal Converging Goals

- Quality outcomes data
- Pay for performance evaluation and issues
- Medicare reductions in payment
- Standards of practice – stroke, carotids, aneurysms
- Defining the appropriate randomized trials
- Coding – angiography bundling
- “Comprehensive Stroke Center” designation
- Coordination of meetings / content
  - annual meetings, fellows courses
- Refining standards of training in Endovascular
- Generating resident interest in Neurovascular
Other SNIS Efforts

- Developing a Fellows Committee within SNIS Executive Committee to address vital needs such as getting jobs out of training and developing future leadership of the SNIS and JNIS

- SNIS will be represented at upcoming FDA hearing on the future of the Gateway/Wingspan HDE
Healthy membership growth of this multi-discipline society

Successful annual meetings and more involvement with CV Section

Indexing of JNIS journal in Pub Med, and transition to bi-monthly publication
Brain Attack Coalition

Dr. Sander Connolly
Membership Update

Dr Gregory J. Zipfel
Membership Update
Gregory J. Zipfel, MD
# CV Section Membership Update

## Current Members

<table>
<thead>
<tr>
<th>Category</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>Active</td>
<td>360</td>
</tr>
<tr>
<td>International</td>
<td>67</td>
</tr>
<tr>
<td>Adjunct Associate</td>
<td>42</td>
</tr>
</tbody>
</table>

**Total Current Members:** 469

## Members Lost

<table>
<thead>
<tr>
<th>Category</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>Suspended</td>
<td>1</td>
</tr>
<tr>
<td>Resigned</td>
<td>2</td>
</tr>
<tr>
<td>Deceased</td>
<td>3</td>
</tr>
</tbody>
</table>

## Applications for vote

<table>
<thead>
<tr>
<th>Category</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>Active</td>
<td>13</td>
</tr>
<tr>
<td>International</td>
<td>0</td>
</tr>
<tr>
<td>Adjunct Associate</td>
<td>0</td>
</tr>
</tbody>
</table>
Initiatives to broaden membership

- E-blast to graduates requesting active membership
  - Sent September 12, 2011

- E-blast to complementary societies
  - NASBS E-blast – To be sent in October 2011
  - SNIS E-blast – To be sent in October 2011

- E-blast to CV Section Members to identify potential new members
  - Sent September 12, 2011

- These e-blasts will continue on annual basis
Issues to consider

- Many applications from non-neurosurgeons are “in progress” due to lack of sponsors
  - Should we respond to these potential members with a short list of willing sponsors with email addresses?
- Completed membership applications currently require approval by EC, which delays active membership by several months at times
  - Should we remove the EC approval from our process?
## Membership Applications for Vote

<table>
<thead>
<tr>
<th>Applicant</th>
<th>Institution / Location</th>
<th>Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pascal Jabbour</td>
<td>Thomas Jefferson</td>
<td>Active</td>
</tr>
<tr>
<td>Brian Jankowitz</td>
<td>University of Pittsburgh</td>
<td>Active</td>
</tr>
<tr>
<td>Alexander Coon</td>
<td>Johns Hopkins</td>
<td>Active</td>
</tr>
<tr>
<td>Chris Eddleman</td>
<td>UT Southwestern</td>
<td>Active</td>
</tr>
<tr>
<td>Gregory Fauthereee</td>
<td>Baton Rouge, LA</td>
<td>Active</td>
</tr>
<tr>
<td>Deanna Sasaki-Adams</td>
<td>SLU</td>
<td>Active</td>
</tr>
<tr>
<td>Albert Kim</td>
<td>Washington U / St. Louis</td>
<td>Active</td>
</tr>
<tr>
<td>Greg Velat</td>
<td>U of Florida</td>
<td>Active</td>
</tr>
<tr>
<td>Lucino Castillo</td>
<td></td>
<td>Active</td>
</tr>
<tr>
<td>Anil Nair</td>
<td>Albany Medical Center</td>
<td>Active</td>
</tr>
<tr>
<td>Kenneth Snyder</td>
<td>U of Buffalo</td>
<td>Active</td>
</tr>
<tr>
<td>Koji Ebersole</td>
<td>U of Miami</td>
<td>Active</td>
</tr>
<tr>
<td>Hosam Al-Jehani</td>
<td>Verdun, Quebec</td>
<td>Active</td>
</tr>
</tbody>
</table>
Fundraising Committee

Dr Brian Hoh
Dr Peter Rasmussen
Action item: Send Prospectus out to CV Section Membership to initiate additional funding through personal relationships.
Research Fellowship Committee

Dr. Robert J. Dempsey
Dr. Peter Rasmussen
CV Research Award Update

Two $15K Resident Research Awards for 2011:

- Dr Narlin Beaty, Maryland University: “Involvement of myeloid relate protein 8/14 in aneurysmal subarchnoid hemorrhage”
- Dr Bartley Mitchell, Baylor College of Medicine: “Endovascular delivery of small-interfering RNA and molecular therapeutic strategies in CNS disorders”

Awards to be acknowledged at the 2012 AANS/CNS CV Section Meeting.

Renamed the “Robert J Dempsey MD Cerebrovascular Research Award” by the CV Section Exec Council
Cerebrovascular Research Award Update – 2011

As Chair of the Cerebrovascular Research Award, I am pleased to report the Cerebrovascular Section of the American Association of Neurological Surgeons and The Congress of Neurological Surgeons once again awarded two $15,000 Resident Research Awards in Cerebrovascular Disease in 2011. Judged to be winners of this award for 2011 are:

Dr. Narlin Beaty from Maryland University for his study, “Involvement of Myeloid Related Protein 8/14 in Aneurysmal Subarachnoid Hemorrhage”, and Dr. Bartley Mitchell from Baylor College of Medicine for his study, “Endovascular Delivery of Small-Interfering RNA and Molecular Therapeutic Strategies in CNS Disorders”. Winners of this award will be acknowledged at the 2012 AANS/CNS Cerebrovascular Section Meeting.

At the last Joint Section Meeting, the Joint Section very kindly named the Cerebrovascular Research Award, “Robert J. Dempsey, MD, Cerebrovascular Research Award”, which is quite an honor. The Joint Section took on the responsibility of fundraising to establish ongoing funding. It will be important that ideas be considered regarding this assuring future funding. The reviewers for the past year were: Drs. Robert Dempsey, Robert Friedlander, Dandan Sun, and G. Edward Yates. We appreciate their help and hope they will be able to continue in the future. It may be appropriate for us to coordinate another basic scientist in the near future.

Assuming the funding will again be successful, information and applications for the 2012 award will be sent to program directors, neurosurgery journals, and appropriate websites in October and November, with applications due by March 1, 2012. We look forward to another year promoting resident research.

Sincerely,

Robert J. Dempsey, MD
Chairman and Manucher J. Javid
Professor of Neurological Surgery
Department of Neurological Surgery

RJD:lvb
Newsletter Committee

Dr. David
Dr. Bulsara
Action Item: Check on e-blast distribution list.
Website Committee

Dr. Gregory Zipfel
Dr. Bob Carter
Update

- Continuing with updates to existing website
- New website design in progress
  - RFP sent in Fall 2011
  - 4 Proposals ultimately received and reviewed
  - 2 Finalists
    - Formal interview at WashU
    - Proposals critiqued by WashU Director of Marketing
    - References contacted
  - Website committee recommendation = Vividsites
<table>
<thead>
<tr>
<th><strong>VividSites</strong></th>
<th><strong>Comments</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Development Cost</td>
<td>$39,400</td>
</tr>
<tr>
<td>Modifications Cost</td>
<td>$80-100/hr</td>
</tr>
<tr>
<td>Hosting Cost</td>
<td>$55 per month</td>
</tr>
<tr>
<td>Timeline</td>
<td>12-16 weeks</td>
</tr>
<tr>
<td>Content Management System</td>
<td>VS-CMS (proprietary)</td>
</tr>
<tr>
<td></td>
<td>3 hr of training provided / no personnel limit</td>
</tr>
<tr>
<td>Mobile functionality</td>
<td>Not specified</td>
</tr>
<tr>
<td>Past Work</td>
<td>• In business since 1989</td>
</tr>
<tr>
<td></td>
<td>• Visually very appealing</td>
</tr>
<tr>
<td></td>
<td>• Significant healthcare experience (Ortho, OB-GYN)</td>
</tr>
<tr>
<td></td>
<td>Negotiated 10% discount ($35,460)</td>
</tr>
<tr>
<td></td>
<td>Well within standard</td>
</tr>
<tr>
<td></td>
<td>Well within standard</td>
</tr>
<tr>
<td></td>
<td>Dependent on our ability to provide content</td>
</tr>
<tr>
<td></td>
<td>Could ask for 3rd party CMS (easier to switch to different web design company in future)</td>
</tr>
<tr>
<td></td>
<td>Will be added at no extra cost</td>
</tr>
<tr>
<td></td>
<td>• Proven track record</td>
</tr>
<tr>
<td></td>
<td>• Highly recommended by Ortho and OB-GYN at WashU</td>
</tr>
</tbody>
</table>
Review of previously raised issues

- Development cost – HIGH!!
  - Reduce scope of RFP in attempt to reduce cost
    - Not very feasible
  - Approach other vendors hoping for lower estimate
    - Very similar costs (all in the high $30K’s)
  - Approach industry to assist with cost
    - Provide Corporate Partners page with listing of companies that provided support – should we proceed?

- Hosting costs – LOW
  - Manageable by section
Next steps

- Pursue formal contract with Vividsites if approved by CV section EC
<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Topic</th>
<th>Moderators</th>
<th>Speakers</th>
<th>Objectives</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday, April 28, 2011, 7:00 – 8:00 PM EST</td>
<td>Evolving Approaches To ICH</td>
<td>E. Sander Connolly, Jr., Brian L. Hoh</td>
<td>Issam A. Awad, Daniel F. Hanley</td>
<td>1-Review the epidemiology, pathophysiology and natural history of intracerebral hemorrhage. 2- Review minimally invasive options for ICH. 3- Update on clinical trials results</td>
<td></td>
</tr>
<tr>
<td>Thursday, May 12, 2011, 7:00 – 8:00 PM EST</td>
<td>Carotid Disease</td>
<td>Andrew J. Ringer, John A. Wilson</td>
<td>Jose Biller, Robert E. Harbaugh, L. Nelson Hopkins, III</td>
<td>1- Review the role of atherosclerosis in stroke. 2- Review treatment options and decision making for carotid stenosis. 3- Review recent data comparing carotid endarterectomy and carotid stenting.</td>
<td></td>
</tr>
<tr>
<td>Thursday, June 09, 2011, 7:00 – 8:00 PM EST</td>
<td>Moyamoya Disease</td>
<td>Christopher S. Ogilvy, Gregory J. Zipfel</td>
<td>Colin Derdeyn, R. Michael Scott, Gary K. Steinberg</td>
<td>1- Review the pathophysiology, epidemiology, and natural history of pediatric and adult Moyamoya disease. 2- Review the clinical evaluation and imaging findings of Moyamoya disease. 3- Understand modern surgical options for Moyamoya disease.</td>
<td></td>
</tr>
</tbody>
</table>

http://w3.cns.org/university/webinar/index2.asp#vascular
Bylaws/Rules & Regulations Committee

Dr. Charles Prestigiacomo
Action item: 2 new proposals approved at the CNS meeting Executive Council Meeting.
Nominating Committee

Dr. John Wilson
Dr. Murat Gunel
Old Business
Junior Resident / Fellow

Endovascular Course

Dr Mocco
CV Section “Hands On” Resident Course

Directors:
J Mocco
Bernard Bendok
CV Section “Hands On” Resident Course

Goal:

Generate interest in Endovascular among Neurosurgery residents
- Target junior residents who may or may not be interested
- Provide Hands-On exposure through simulators/flow models
- Foster Mentorship opportunities for residents with Endo Faculty
- Provide “Gateway” to the CV Meeting to potentially increase attendance
CV Section “Hands On” Resident Course

Brief Rundown:
45 residents attended
27 fellows attended
28 faculty
45 Hands-On Stations
13 Simulators

Current dollar estimate:
$123,500 from industry
$96,451 operating costs
Neuropoint Alliance

Dr Kevin Cockroft
3C meeting

Dr Elad Levy
Dr Adnan Siddiqui
“Mistakes are the portals of discovery.”
– James Joyce

F O U R T H A N N U A L
C E R E B R O V A S C U L A R
C O M P L I C A T I O N S
C O N F E R E N C E

J U N E 2 3 - 2 6 , 2 0 1 1
F O U R S E A S O N S R E S O R T • T E T O N V I L L A G E , W Y O M I N G

Don’t Miss Out!

Register Early. There are only a limited number of spaces for this meeting.

Visit our website for conference details and online registration.

www.3Cmeeting.com

T H I S C O N F E R E N C E I S D E S I G N E D F O R
• NEUROSURGEONS
• INTERVENTIONAL NEURORADIOLOGISTS
• NEUROLOGISTS
• SCIENTISTS
• ALL PRACTITIONERS INVOLVED IN INTERVENTIONAL PROCEDURES
Joint Meeting – Cerebrovascular Society of India

Dr Saleem Abdulrauf
Cerebrovascular Society of India
Combined meeting

- CV Surgery Society of India – Mumbai
BAF Update

- September established by the U.S. Senate as National Brain Aneurysm Awareness Month.
- First lobbying initiative with a day on Capitol Hill in May 8-9, 2012
- Developing a medical educational lecture to be delivered via PRI-MED conferences targeting primary care professionals and nurses. The lecture will be CME accredited. Boston, MA on Nov 15-18 2012
- Awarded 8 grants this year totaling $160,000.
- Finished the year at $800K+
- Research grant symposium will be in St. Louis on September 20, 2012
- Moving forward with a BAF non-charitable status in Canada
New Business
COSS Trial

Dr. Hanjani)
EC-IC Bypass for Stroke – is this the end of the line or a bump in the road?


On behalf of the Cerebrovascular Section of the American Association of Neurological Surgeons (AANS) and Congress of Neurological Surgeons (CNS)

The results of the recently published Carotid Occlusion Surgery Study (COSS) trial\(^1\) have already been touted by some as the final death knell for bypass surgery in ischemic cerebrovascular disease\(^2\). As with all influential clinical trials, however, it is important to scratch beneath the surface, in order to examine the design and execution of the study carefully before trying to decide what the results of the trial should mean for every day clinical practice.
COSS – the background

The historical context of the COSS trial dates back to the negative results of the much discussed EC-IC bypass trial published in 1985. That study failed to show a benefit for superficial temporal artery (STA) – middle cerebral artery (MCA) bypass in over a thousand patients with symptomatic internal carotid or middle cerebral atherosclerotic disease not amenable to carotid endarterectomy; most were patients with carotid occlusion. The study was hotly debated, and criticized for several reasons including the large number of subjects operated on outside the study, raising concerns of selection bias. Another frequently cited concern was the lack of hemodynamic selection criteria. Over the next two decades, a number of studies emerged focused on evaluating the importance of hemodynamic impairment in stroke risk. The most relevant in terms of the subsequent COSS study, was the prospective blinded observational St Louis Carotid Occlusion Study (STLCOS) which utilized quantitative positron emission tomographic (PET) imaging to identify misery perfusion, defined as increased oxygen extraction fraction (OEF). Eighty one symptomatic patients with symptomatic carotid occlusion were enrolled and those with misery perfusion (n= 39) were found to have a significantly higher risk of ipsilateral stroke, 26.5 % vs. 5.3% at 2 years. Post-hoc retrospective subgroup analysis of the STLCOS data was then used to identify a higher risk subset for inclusion into a trial, and further post-hoc analysis was used to identify a ‘more specific’ OEF threshold, to define a very high risk cohort for COSS.
COSS – the results

COSS was undeniably a gargantuan effort led by a team of dedicated investigators who had examined their own existing preliminary data from the STLCOS closely. The study recruited patients in a 2 step process; potential participants with TIA or ischemic stroke in the hemispheric territory of an occluded carotid artery within the preceding 120 days were eligible to undergo PET at COSS-approved sites. Patients with ipsilateral-to-contralateral hemispheric ratios of mean regional OEF $>$0.13 were randomized to either medical management or surgical intervention with STA-MCA bypass. The primary outcome was defined as all stroke and death within 30 days after surgery and ipsilateral ischemic stroke within 2 years. Based on STLCOS, and the surgical cohort of the EC-IC bypass trial, the investigators had projected primary outcome rates of 40% for the medical group and 24% in the surgical group, with a sample size estimate of 372 patients. The study was prematurely halted after enrollment of 195 randomized patients based on an interim futility analysis. The main results from the analysis of randomized patients were as follows:

1. The 2 year primary outcome rates were not significantly different at 21% in the surgical group and 22.7% in the medical group
2. The 30 day (peri-operative) event rate in the surgical group was 15%
3. Mean OEF ratio in the surgical group improved from baseline at time of 30-60 day follow-up PET; repeat PET imaging was not performed in the medical group.

Although the primary analysis of COSS was by intent-to-treat, most patients received the treatment to which they were randomized and there was little cross-over. Other strengths of the study were the remarkably good follow-up rates (99%), blinded adjudication of endpoints, and standardized follow-up. Nonetheless several aspects of the study warrant further discussion.
The medical group – unexpectedly low stroke rate

Although the overall stroke rate in the surgical group was not significantly different than initially estimated (the relatively high peri-operative morbidity was counteracted by the low 6% stroke rate thereafter), the medically treated group had a substantially lower risk of stroke than originally hypothesized, 22.7% vs 40%. Much focus has been placed on the notion that improvements in medical therapy, particularly statins, are responsible for this difference in projected stroke rates. It is undeniable that improvements in medical management are leading to reduction in stroke incidence compared to historical controls; in the recent SAMMPRIS trial, for example, an aggressive medical management strategy, including LDL target below 70 mg/dl, as well as vigilant targeting of blood pressure, diabetes, smoking, excessive weight and inactivity, resulted in substantially lower stroke rates in patients with intracranial stenosis. However these measures were far beyond the standard therapies employed in the COSS trial, and the attribution of a 17% absolute risk difference and almost 50% relative risk reduction to standard measures, such as higher utilization of statins, seems to credit medical therapies with a benefit larger than previously demonstrated. In the large scale SPARCL study, for example, statins showed a clear benefit, but only an absolute risk reduction of about 5% and relative risk reduction in the range of 25% for large vessel disease.
It is, therefore, worth examining other potential reasons for the lower observed stroke rate in the medical group, reasons which may indicate that the COSS criteria for identifying the very high risk patients failed to do so.

1. Firstly, concerns have been raised about the specific PET methodology employed for patient selection in the trial\textsuperscript{12}. Understanding these concerns requires some discussion of the nuances of PET imaging. The original STLCOS study defined high OEF based on the ratio of left-right hemispheric quantitative OEF values outside the normal range; this methodology differed from the absolute (as opposed to ratio) threshold utilized in some other studies\textsuperscript{13,14}. Regardless, the quantitative technique requires repeated arterial sampling during scanning. Subsequent post-hoc analysis of the STLCOS data was performed to demonstrate that a simpler, but semi-quantitative, count-based ratio technique for OEF determination showed similar results in terms of predictive value\textsuperscript{15}. Further post-hoc analysis was then used to identify a new threshold for OEF using this modified technique\textsuperscript{8}. Thereafter COSS also made concessions to expand recruitment, such as allowing patients with contralateral carotid stenosis to be eligible (which could impact hemispheric ratios). Subsequent examination by others of the PET methodology and threshold used in COSS suggests that the hemispheric ratio count-based method of COSS identifies a different set of patients as flow compromised compared to those identified by quantitative PET, the previous gold standard\textsuperscript{12}. The implication would be that the COSS PET criteria failed, ultimately, to identify the truly hemodynamically high risk cohort.

2. Secondly, COSS relied on retrospective subgroup analysis of the STLCOS cohort, using features of clinical presentation, to help define the clinical criteria for selecting a high risk-group\textsuperscript{8,9}. However, there are intrinsic weaknesses concerning the use of retrospective post hoc analysis to evaluate prognostic factors\textsuperscript{16}. Defining optimal cutpoints for risk stratification in this manner is known to predispose to overestimation of the true difference in event rates between groups\textsuperscript{17,18}. 
Taking these concerns in aggregate, the efforts to select the highest risk group for inclusion in COSS may have failed due to reliance on posthoc analysis, and the specific thresholds used to define impaired hemodynamics.

*Peri-operative morbidity – is this the best we can do?*

As with many interventional trials, COSS included a certification process for the surgeons. Operator experience is well recognized as an important element in studies examining new techniques or technologies, as evidenced by fairly rigorous certification processes mandated by recent trials such as CREST and SAMMPRIS\(^{10,19}\); although STA-MCA bypass has been described and performed since the 1960s, the volume of the procedure dropped precipitously following the publication of the EC-IC bypass trial and the subsequent CMS (Center for Medicare and Medicaid Services) decision to withdraw reimbursement for the procedure. At first glance, it may appear that COSS took measures to ensure that experienced operators were engaged in the study. However, closer examination reveals that this process included such options as a 2 day training course, or allowing surgeons with less than 10 prior case experience to perform the case under supervision. Presumably these concessions were driven by the desire to expand the number of centers and enhance recruitment, but raise some concerns regarding surgeon experience. Although the investigators point out that the perioperative stroke rate was not found to be correlated with the certification method, the sample size of 93 patients, operated by 30 different surgeons, is likely too small to detect differences. The volume-outcome effect in many facets of cerebrovascular surgery, including bypass surgery, has been well illustrated based on larger regional and national databases\(^ {20-23}\). An analysis of 558 EC-IC bypass admissions from the Nationwide Inpatient Sample (NIS) hospital discharge database found a clear association between volume and improved discharge outcome, with an OR of 0.45 for a 10-fold increase in caseload\(^ {20}\).
Although the high patency rates in the COSS trial may be considered an indicator of overall technical success and operator experience, the volume-outcome association in the NIS study was actually most evident when considering hospital volume, rather than individual surgeon caseload; this emphasizes the potential influence of hospital related factors such as specialized neuroanesthesia, dedicated neuro-intensive care units, and specialized nursing in the outcome of the patients, beyond only the technical aspect of the surgery. Although the observed 15% postoperative event rate is within the range anticipated from the original EC-IC bypass trial, with improvements in anesthetic technique, critical care, and overall peri-operative management, most surgeons would have expected some improvement in peri-operative morbidity compared to 25 years ago. Recognizing the tendency for publication bias, published reports from experienced centers would still suggest that a 15% perioperative stroke rate in patients with occlusive disease, even hemodynamically brittle patients with potentially higher surgical risks of surgery, is not the best that can be achieved²⁴-²⁷. Ultimately, for a similarly sized trial with identical post 30 day stroke rates to demonstrate benefit would require peri-operative stroke risk to be less than half of what was actually achieved in COSS.
Crossing curves—did we wait long enough?

COSS does provide us with the insight that, after the peri-operative period, bypass patients appeared to experience a clear reduction in subsequent event rate. This is in line with the interim results of the Japanese EC-IC bypass Trial (JET), which indicate similar reduction in stroke rates post bypass. In that study, an apparent zero percent stroke rate in the peri-operative period leads to a conclusion in favor of bypass\(^{(28,29)}\), although the final results have not been subjected to peer review and publication. COSS has also demonstrated well the concept of improved hemodynamics post bypass with follow-up PET studies in the operated patients. These data affirm the conceptual basis of revascularization with EC-IC bypass, and suggest that if perioperative stroke rates could be curbed, benefit is likely. Even with the existing event rates, is it possible that a sustained effect of bypass beyond the 2 year endpoint would ultimately outweigh the immediate perioperative down-side? Although the Kaplan Meier curves at 2 years are not significantly different, a continuation of the curves could result in a crossover benefiting surgery. In fact, if all patients enrolled completed additional follow-up, the study would have adequate power to demonstrate a significant benefit of surgery by 5 years. This projection presumes an ongoing steady stroke rate in both groups beyond 2 years, an assumption which, admittedly, may not be entirely justifiable. Spontaneous improvement in hemodynamics without surgery, presumably due to development of collaterals, has been reported in small scale observational studies; however, discrepant results have emerged from different reports as to whether continued improvement occurs with longer follow-up\(^{(30)}\), or changes occur only in the first few months of observation\(^{(31)}\), and would not affect longer term stroke risk thereafter. Unfortunately, follow-up PET imaging was not performed for the medical group in COSS, and longer term follow-up is not currently available to elucidate the apparent eventuality of ‘crossing curves’ in the outcome analysis.
It should also be noted that the study was halted due to futility analysis, based on the improbability of demonstrating the effect size that had originally been hypothesized (24% surgical vs 40% medical at 2 years); however, a risk difference of 10% in favor of surgery was still viable, but would have required a substantial increase in sample size to 986 patients; this was not felt to be feasible, due to the cost and resources required to expand the study. The practicalities of performing such large scale studies notwithstanding, a 10% absolute reduction in stroke risk would still be a clinically important and meaningful outcome which was not addressed by the trial.
What about the ‘hot’ patient?

Recurrently symptomatic patients, especially those with severe clinically hemodynamic disease who become ischemic with postural or blood pressure variations, represent a potentially important subgroup that is not well addressed by COSS. The study allowed enrollment up to 120 days after most recent event, and by design, required patients to be clinically stable enough to be sent for PET scan (sometimes even requiring air travel to a PET center) to determine final eligibility. Prior studies of cerebrovascular atherosclerotic disease have repeatedly demonstrated that the highest risk for recurrent events tends to be in the early period after initial symptoms\textsuperscript{32-34}, generally within a 2 week timeframe, and declining thereafter. Given that the mean time from symptoms to enrollment in COSS was about 72 days, the enrollees were potentially pre-selected to be the inherently more stable patients. The fact that no strokes occurred in the median 6 day period from randomization until surgery further suggests that these patients were not in their most acute period of risk. Additionally, COSS only required patients to have suffered a single ischemic event in order to be eligible for the trial. Critics of this approach may argue that a single incident event at the time of carotid occlusion is likely to represent a single embolic event unlikely to recur under medical therapy; on the other hand, the approach in COSS may seem reasonable as final eligibility was ultimately determined by hemodynamic criteria. Nonetheless, it also seems feasible that some proportion of such presumed hemodynamic patients would plateau quickly in their stroke curves as collaterals develop, whereas others would remain high risk, and would declare themselves with recurrent ischemic events as failures of medical therapy. Information regarding the ischemic history of enrolled patients are not currently published, but it seems that recurrently ischemic patients with hemodynamic impairment may not be well represented in COSS, and may still be the ones to target for revascularization.
Is stroke the only endpoint that matters?
Even as COSS has halted, the ancillary study, Randomized Evaluation of Carotid Occlusion and Neurocognition (RECON) continues to follow patients for cognitive outcomes. With small numbers, the study is likely not powered to definitively address the impact of revascularization on cognitive function, but may still provide further data to support the notion that increased cerebral blood flow has direct clinical benefits aside from reducing stroke risk. Improvement in cognitive function after bypass, and even after carotid endarterectomy in flow–impaired patients, have been reported. Furthermore preliminary study in patients with fixed neurological deficits has shown electrophysiological and clinical evidence of improvement post bypass, and the intriguing potential of increased brain volume after bypass for ischemic states has been documented in small studies.
The bottom line

Despite the efforts of the COSS investigators, the trial was ultimately underpowered to detect a benefit of surgery, primarily due to the overestimation of expected event rate in the selected population. The PET methodology utilized was less rigorous than previously used, and the posthoc ‘optimal’ selection criteria may have contributed to a failure in identifying the true high risk group. Ultimately, in the years since the negative 1985 EC-IC bypass trial, surgical revascularization for carotid occlusion has become increasingly restricted to a small, very select population of patients who experience refractory symptoms despite maximal medical therapy \(^{26,42}\). Although COSS has been unable to provide any evidence that we should expand those indications, at the same time, we still have reason to believe that a select population may in fact benefit in long-term stroke risk from the surgery at specialized centers which can offer the procedure with sufficiently low peri-operative morbidity. Looking beyond stroke risk reduction, cognitive or functional benefits are also an area of future investigation which should not be ignored. Careful selection and limited application with an eye to future developments, rather than complete abandonment, is warranted.


28. Ogasawara K, Ogawa A. [jet study (japanese ec-ic bypass trial)]. Nihon Rinsho. 2006;64 Suppl 7:524-527


37. Lin MS, Chiu MJ, Wu YW, Huang CC, Chao CC, Chen YH, Lin HJ, Li HY, Chen YF, Lin LC, Liu YB, Chao CL, Tseng WY, Chen MF, Kao HL. Neurocognitive improvement after carotid artery stenting in patients with chronic
internal carotid artery occlusion and cerebral ischemia. Stroke. 2011;42:2850-2854


NINDS Update

Dr. Robert Friedlander
- Action item: Dr Friedlander to provide a list of the current programs
Senior Society Matrix/Milestones and Modules

Dr. Sander Connolly
Massimo Collice award for cerebrovascular malformations

Dr. Giovanni Broggi
The Massimo Collice Foundation for Neuroscience announces an annual international prize of 10,000 euros for experimental or clinical research on Cerebral vascular malformations.

This is an award sponsored by his widow, and is aimed at the best published paper in the preceding year by a first author less than 40 years of age.

Bob Spetzler will run the selection committee along with a number of others

The prize is intended to deepen training of the applicant in any specialized neurosurgical area, and will be delivered at the 2012 Annual meeting of the AANS during the Cerebrovascular Section.

Participants younger than 40 years old on December 31, 2011 are eligible to apply and should be the lead author of the work.

The study must have been published in a peer-reviewed journal in 2011 and may not have already received another award.

The deadline for submission is January 31, 2012.  www.massimocolliceonlus.com
Meri Institute/CV Sect
Resident & Fellows
Courses

Dr. Adam Arthur
Dr. Erol Veznedaroglu
Dr. J Mocco
Dr. Brian Ho
SVIN Liaison

Dr. J Mocco
Action item: Bylaws change to have reciprocal representation with the SVIN.
Thank you!